Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)
July 31, 2019 12:12 ET
|
Eloxx Pharmaceuticals
On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S., Europe, Israel and Canada in 2019 Company to host webcast and conference call...
Eloxx Pharmaceuticals to Present at the 39th Annual Canaccord Genuity Growth Conference on August 8th, 2019
July 17, 2019 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on August 7, 2019
July 16, 2019 08:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 24, 2019 16:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced the closing of its underwritten public offering of 3,833,334 shares of its...
Eloxx Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Stock
June 20, 2019 08:36 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced the pricing of an underwritten public offering of 3,333,334 shares of its...
Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 19, 2019 16:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass, June 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced that it intends to offer and sell shares of its common stock in an underwritten...
Eloxx Pharmaceuticals’ Phase 2 Study of ELX-02 in Cystinosis Receives Authorization of Clinical Trial Application (CTA) by Health Canada and Funding from Genome Quebec and Genome Canada
June 10, 2019 08:00 ET
|
Eloxx Pharmaceuticals
Dr. Paul Goodyer, a Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, will be the principal investigator in the Phase 2 clinical trial Genome Quebec and...
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference (ECFS)
June 06, 2019 12:30 ET
|
Eloxx Pharmaceuticals
ELX-02 demonstrates dose-responsive pronounced increases in functional CFTR and read-through in organoids, human bronchial epithelial (HBE), and Ussing chamber systems ELX-02 increases CFTR mRNA to...
Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update
May 09, 2019 07:00 ET
|
Eloxx Pharmaceuticals
Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 demonstrated: dose dependent...
Eloxx Pharmaceuticals Presents Positive New Data at the Association for Research in Vision and Ophthalmology “ARVO” 2019 Annual Meeting
May 02, 2019 10:30 ET
|
Eloxx Pharmaceuticals
Eloxx is evaluating several of its eukaryotic ribosomal selective glycoside (ERSG) molecules in IND-enabling studies for use in the treatment of inherited retinal diseases with an initial focus on...